Zhuhai Sailong Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019
April 29, 2020 at 01:13 am IST
Share
Zhuhai Sailong Pharmaceutical Co.,Ltd. announced earnings results for the full year ended December 31, 2019. For the full year, the company announced sales was CNY 293.466 million compared to CNY 436.272 million a year ago. Operating income was CNY 32.490 million compared to CNY 70.191 million a year ago. Net income was CNY 27.483 million compared to CNY 60.904 million a year ago. Basic earnings per share from continuing operations was CNY 0.1718 compared to CNY 0.3807 a year ago.
Sailong Pharmaceutical Group Co Ltd, formerly Zhuhai Sailong Pharmaceutical Co Ltd, is a China-based company principally engaged in the research and development, production and sales of pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and preparations, as well as providing technical services. The Companyâs main products include monosialin tetrahexose ganglioside sodium injections, brain protein hydrolyzate for injections, clindamycin phosphate for injections, pantoprazole sodium for injections and milrinon injections, among others. Through its subsidiaries, the Company is also engaged in the sales of scraps, provision of technical services and sales promotion. The Company mainly conducts its businesses with domestic market.